Sanofi's €250m AI-driven R&D collaboration for metabolic disease

The partnership will focus on metabolic diseases, such as diabetes. UK-based Exscientia will manage the compound design using its AI-based screening platform, while France-based Sanofi will oversee the chemistry synthesis. Exscientia's platform is used to identify and validate combinations of drug targets through an iterative process according to COO, Mark Swindell. He told us, "Our algorithms efficiently evolve new novel compounds as part of a rapid design, make test analyse cycle. The AI algorithms rapidly learn from each round of synthesis and assay, automatically driving designs towards the desired end goals with great rapidity."